Prognostic role of estrogen receptor (ER) expression in breast cancer (BC) metastases and its dynamics from primary to metastatic disease: Results from a large multicentric cohort of patients with phenotypically stable ER+(≥10%)/HER2- BC.
Federica Miglietta(University of Padua), Maria Vittoria Dieci(Istituto Oncologico Veneto), Angelo Paolo Dei Tos(University of Padua), Andrea Vingiani(Istituti di Ricovero e Cura a Carattere Scientifico), Andrea Botticelli(Policlinico Umberto I), Marina La Commare, Valentina Guarneri(Istituto Oncologico Veneto), Pietro Napolitano(Istituto Oncologico Veneto), Matteo Fassan(University of Padua), Tommaso Giarratano(Istituto Oncologico Veneto), Giovanni Faggioni(Istituto Oncologico Veneto), Giancarlo Pruneri(University of Milan), Lorenzo Nicolè(University of Padua), Carlo Alberto Giorgi(Istituto Oncologico Veneto), Giuseppe Fotia, Gaia Griguolo(University of North Carolina at Chapel Hill), Federico Piacentini(Azienda Unita' Sanitaria Locale Di Modena), Davide Massa(University of Padua), Matilde Cacciatore(Ca' Foncello Hospital), Claudio Vernieri(Fondazione IRCCS Istituto Nazionale dei Tumori)
Cited by 0
Related Papers
Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial
|The Lancet|2012|2.1k
Soft tissue and visceral sarcomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2018|1.6k
Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial
|The Lancet Oncology|2014|1.2k
Soft tissue and visceral sarcomas: ESMO–EURACAN–GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up☆
|Annals of Oncology|2021|978
Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
|Annals of Oncology|2023|830